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Abstract
Background:  The effects of histone deacetylase inhibitor (HDACi) treatment on SV40
transcription and replication were determined by monitoring the levels of early and late expression,
the extent of replication, and the percentage of SV40 minichromosomes capable of transcription
and replication following treatment with sodium butyrate (NaBu) and trichostatin A (TSA).
Results: The HDACi treatment was found to maximally stimulate early transcription at early times
and late transcription at late times through increased numbers of minichromosomes which carry
RNA polymerase II (RNAPII) transcription complexes and increased occupancy of the transcribing
minichromosomes by RNAPII. HDACi treatment also partially relieved the normal down-
regulation of early transcription by T-antigen seen later in infection. The increased recruitment of
transcribing minichromosomes at late times was correlated to a corresponding reduction in SV40
replication and the percentage of minichromosomes capable of replication.
Conclusion: These results suggest that histone deacetylation plays a critical role in the regulation
of many aspects of an SV40 lytic infection.
1. Background
Structural and biological changes in chromatin structure
are brought about by changes in the activity of histone
acetyltransferases (HATs) and histone deacetylases
(HDACs) which add or remove acetyl groups from lysine
residues on histone tails respectively. It has been well
established that inhibition of HDAC activity is character-
ized by two important changes within the cell (i) an
increase in the amount of hyperacetylated histones [1]
and (ii) an increase in the level of transcription of certain
genes [2,3]. However we know little about the specific
mechanisms underlying the relationship between HDAC
inhibition (HDACi) and alterations in gene expression at
the molecular level. Since remodeling of chromatin struc-
ture plays a vital role in the regulation of gene expression
[4] the enzymes involved in this modification process
have been used as common targets to alter the pattern of
gene expression.
Sodium butyrate (NaBu) and Trichostatin A (TSA) are
commonly used reversible inhibitors of HDAC activity.
NaBu, a short chain fatty acid occurring naturally in the
body, is a byproduct of anaerobic bacterial fermentation
of dietary fiber [5,6]. TSA, a hydroxamic acid is a fermen-
tation product of Streptomyces and a potent inhibitor of
HDAC activity. NaBu has been extensively used as a
HDAC inhibitor (HDACi), though it is far less efficient
(required in millimolar quantities) in its inhibition capa-
bilities as compared to TSA (required only in nanomolar
quantities). DNA micro array studies have shown that
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almost 7 % to 10% of genes undergo altered gene expres-
sion on HDACi using TSA [7-9]. HDAC inhibitors are now
at the forefront of clinical trials for treatment of various
types of tumors [10,11] either alone or in combination
with other therapies.
During the course of our recent studies investigating the
relationship between histone hyperacetylation and tran-
scription in the SV40 minichromosome model system
[12] we utilized NaBu as an HDACi in part to determine
whether histone hyperacetylation was dynamic in a cod-
ing region undergoing active transcription [12]. In these
studies we observed that there was a significant increase in
the extent of histone hyperacetylation in a coding region
undergoing active transcription following treatment with
NaBu. However, we did not determine whether the
increase in histone hyperacetylation was associated with
an increase in transcription as might have been expected
from the literature or how such an increase in transcrip-
tion might occur in the SV40 model system.
We hypothesized that if SV40 transcription increased
there were two simple ways that inhibition of histone
deacetylation could lead to an increase in transcription.
Either there could be an increase in the number of SV40
minichromosomes which carry RNAP II and undergo
transcription, or the number of transcribing minichromo-
somes remained constant but there was an increase in the
density of RNAPII on those minichromosomes with a cor-
responding increase in the extent of transcription.
We have now determined the effects of HDACi treatment
with NaBu and TSA on SV40 early and late transcription
and replication. Since both transcription and replication
appeared to be affected, we have also determined the
effects of HDACi treatment on the percentage of SV40
minichromosomes undergoing transcription and replica-
tion and the density of RNAPII on transcribing minichro-
mosomes. These studies indicate that inhibition of HDAC
activity can alter an SV40 infection by targeting a number
of different functions of SV40 minichromosomes.
2. Results
2.1. Stimulation of SV40 transcription following inhibition 
of histone deacetylation
We have previously shown that treatment of SV40
infected cells with the HDACi NaBu resulted in a large
increase in the amount of hyperacetylated H4 and H3
associated with transcribing SV40 minichromosomes
[12]. Since treatment with an HDACi frequently results in
the stimulation of transcription of receptive genes [13],
we first determined whether NaBu treatment had a similar
effect on SV40 early and late transcription. In order to
exclude the possibility that the effects observed with NaBu
were specific to this inhibitor and not a result of the inhi-
bition of histone deacetylation, we also used a structurally
distinct second HDACi, trichostatin A [14], in our studies.
In order to determine the effects of HDACi treatment on
SV40 transcription, total proteins and mRNA were iso-
lated 30 minutes post-infection (early) and 48 hours post-
infection (late) from control and HDACi treated SV40
infected cells and analyzed by Western blotting and real
time RTPCR. The proteins were analyzed with antibodies
to T-antigen, to measure the effect on early transcription,
VP-1, to measure the effect on late transcription, and glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) as a
loading control. Similarly, mRNA was quantitated using
primer sets that recognize the VP-1, T-antigen, and
GAPDH mRNAs respectively.
During preliminary studies with various concentrations of
HDACi we observed that treatment with 250 μM NaBu
and 120 nM TSA resulted in significant increases in the
expression of both T antigen and VP1 at appropriate
times, without altering the expression pattern of GAPDH
(data not shown).
Typical examples of the results of a Western blotting anal-
ysis are shown in Figure 1A. Following treatment of SV40
infected cells early in infection (30 mins post infection)
with NaBu (lane 2) and TSA (lane 3) we observed an
increase in the amount of T-antigen present in the cells
compared to an untreated control (lane 1). Similarly,
treatment with NaBu (lane 5) and TSA (lane 6) late in
infection (48 hours post infection) resulted in an increase
in the amount of VP1 compared to the untreated control
(lane 4). We did not observe any significant changes in the
amount of GAPDH present in the cells at early times
(compare lanes 1–3) or late times (compare lanes 4–6)
following treatment with either HDACi.
In order to confirm that the changes in the amount of late
and early proteins in the Western blot analysis following
HDACi treatment were a result of an increase in the
amount of mRNA and not an effect on protein stability,
we next determined the levels of mRNA for VP-1 and T-
antigen in treated and control SV40 infected cells. Because
T-antigen undergoes down-regulation at approximately 8
hours post-infection we also analyzed mRNA expression
at this time in order to determine whether the inhibitors
affected early transcription during down-regulation.
Total RNA was prepared from treated and untreated SV40
infected cells and subjected to real-time RTPCR analysis
with (Figure 1B). Based upon the change in cycle thresh-
old from the real-time RTPCR analysis, we then calculated
the fold increase in transcription at each of the time points
for the treated cells compared to the controls. In untreated
SV40 infected cells as expected, we found early messageVirology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
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present throughout the infection and late message absent
at 30 minutes post-infection, present in extremely small
amounts at 8 hours post-infection, and present in large
amounts at 48 hours post-infection (CT values for treated
and untreated samples are indicated in the figure). The
data shown is the average of at least three separate analy-
ses of treated and untreated samples prepared in parallel.
At 30 minutes post-infection we observed a 3 fold increase
in early message following treatment with NaBu and a 9
fold increase following treatment with TSA. We observed
no late transcription at this time and no subsequent effect
following treatment with the HDACi's. At 8 hours post-
infection treatment with NaBu and TSA resulted in a 2.5
fold and a 4.5 fold increase in early message, respectively.
At this time we again observed little late transcription and
little effect on late transcription with either HDACi. In
contrast, at 48 hours post-infection we observed little
effect on the amount of early message present but a 6 fold
increase with NaBu treatment and an 11 fold increase
with TSA treatment on the amount of late mRNA. We did
not observe any significant effects on the amount of
Effects of HDACi treatment on SV40 transcription Figure 1
Effects of HDACi treatment on SV40 transcription. (a) Total protein extracted from 30 min and 48 hour SV40 infected 
BSC-1 cells and either untreated or treated with 250 μM NaBu or 120 nM TSA were separated using SDS PAGE followed by 
western blot analysis using antibody against T antigen (for 30 mins), VP1 (for 48 hours) and GAPDH (for both 30 mins and 48 
hours). (b) Total RNA extracted from 30 min, 8 hour and 48 hour SV40 infected BSC-1 cells untreated and treated with 250 
μM NaBu or 120 nM TSA were reverse transcribed and the amount of mRNA for T antigen and VP1 were analyzed using real 
time PCR using primer sets against early the coding region and late coding region, respectively. Data is expressed as the fold 
increase in expression levels compared to the mRNA from untreated SV40 infected BSC-1 cells and represent the average of 
three independent experiments.Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
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GAPDH mRNA at any of the times following HDACi treat-
ment (data not shown). Taken together, the Western blot-
ting and real-time RTPCR analyses indicated that the
HDACi treatment stimulated early and late SV40 tran-
scription like many other genes, but that the stimulation
occurred maximally when the genes were being actively
transcribed.
2.2. Inhibition of histone deacetylation results in an 
increase in the number of transcribing SV40 
minichromosomes
Since the increase in SV40 early and late mRNA and pro-
tein following HDACi treatment could be due to an
increase in the number of SV40 minichromosomes under-
going transcription, we first determined whether HDACi
treatment affected the number of SV40 minichromo-
somes carrying RNAPII, an enzyme absolutely required
for eukaryotic transcription. We have previously shown
that SV40 minichromosomes containing RNAPII can be
immune selected with antibody to RNAPII in a ChIP assay
for subsequent studies [12,15] and that the RNAPII on the
SV40 minichromosomes is organized in a pattern consist-
ent with its role in transcription [15].
SV40 minichromosomes from control and HDACi treated
infected cells were harvested in parallel at 30 minutes, 8
hours, and 48 hours post-infection from at least three sep-
arate preparations of SV40 minichromosomes at each
time point and subjected to a ChIP analysis with antibody
to RNAPII followed by real-time PCR amplification for
quantitation. From the CT values obtained from the anal-
yses of HDACi treated and untreated SV40 minichromo-
somes we then determined the percentage of the SV40
minichromosomes that contained bound RNAPII from
each set of samples (Figure 2).
In untreated SV40 minichromosomes we observed
approximately 0.84 ± 0.19% of the total pool of SV40
minichromosomes carrying RNAPII at 30 minutes, 0.04 ±
0.01% at 8 hours, and 1.5 ± 0.16% at 48 hours post-infec-
tion (Figure 2). Our previous published results have
shown that the lower percentage of SV40 minichromo-
somes containing RNAP II at 8 hours post infection is due
the transcriptional switch between down regulation of
early transcription and up regulation of late transcription
occurring at approximately the 8 hour time point [15].
The percentage at 48 hours post-infection was similar but
somewhat smaller than our previous report of approxi-
mately 10% at 48 hours post-infection [12]. The observed
decrease was possibly due to differences in the age of the
cells used in this analysis compared to our previous
report. It was however closer to the 4% which has been
previously reported using very different techniques [16].
In order to determine whether there was an effect on the
number of SV40 minichromosomes carrying RNAPII fol-
lowing HDACi treatment, we then determined the per-
centage of SV40 minichromosomes that contained bound
RNAPII after HDACi treatment. In these analyses we first
determined whether there was any effect on the size of the
pool of minichromosomes resulting from the HDACi
treatment. While we noted that there was no significant
effect on the overall size of the pool of SV40 minichromo-
somes following HDACi treatment at 8 hours and 48
hours there was a small effect at 30 minutes compared to
the corresponding untreated control. At 30 minutes post-
infection we observed CT values of approximately 16.9 in
untreated samples and a CT value of approximately 15. 8
in the HDACi treated samples, at 8 hours post-infection
CT values of approximately 15.3, and at 48 hours post-
infection CT values of approximately 15.5. While treat-
ment with the HDACi inhibitors appeared to slightly
increase the uptake of virus at 30 minutes post-infection,
Effects of HDACi treatment on chromosomes carrying RNA Polymerase II Figure 2
Effects of HDACi treatment on chromosomes carrying RNA Polymerase II. 30 min, 8 hour and 48 hour SV40 mini-
chromosomes either untreated or treated with 250 μM NaBu or 120 nM TSA were immune selected using 10 μl of antibody 
against RNAPII. Data is expressed as the percentage of SV40 minichromosomes containing RNA Polymerase II and represent 
the average of three independent experiments.Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
Page 5 of 11
(page number not for citation purposes)
the similarity in the CT values of the total pool of mini-
chromosomes from the treated and untreated SV40
infected cells at the other times indicated that HDACi
treatment was not significantly affecting the overall size of
the pool of minichromosomes present at those times.
As shown in Figure 2 we observed approximately a tenfold
increase in the percentage of SV40 minichromosomes car-
rying RNAPII following HDACi treatment at each time in
the infection. In the pool of SV40 minichromosomes iso-
lated 30 minutes post-infection the percentage of mini-
chromosomes carrying RNAPII increased from 0.84 ±
0.19% in the untreated control to 10.23 ± 1.99% follow-
ing NaBu treatment and 12.42 ± 2.17% following TSA
treatment. Similarly, at 8 hours post-infection the values
increased from 0.04 ± 0.01% in the control to 0.72 ±
0.21% following NaBu treatment and 1.27 ± 0.14% fol-
lowing TSA treatment. Finally, at 48 hours post-infection
the percentages of SV40 minichromosomes carrying
RNAPII increased from 1.5 ± 0.16% in the control to 9.47
± 1.29% following NaBu treatment and 13.63 ± 1.5% fol-
lowing TSA treatment.
Since the size of the pool of SV40 minichromosomes did
not change appreciably following HDACi treatment, the
increase in SV40 minichromosomes carrying RNAPII
appeared to result from a corresponding reduction in
SV40 minichromosomes undergoing some other biologi-
cal processes. This increase in the percentage of SV40 min-
ichromosomes capable of transcription suggested that
HDAC activity might play a critical role in controlling the
biological fate of SV40 minichromosomes.
2.3. HDACi treatment inhibits SV40 replication
Since SV40 replication is an important biological process
occurring at 48 hours post-infection, we hypothesized
that the increase in SV40 minichromosomes carrying
RNAPII at this time might cause a corresponding decrease
in the SV40 minichromosomes capable of replication. In
order to test this hypothesis, we first measured the incor-
poration of tritiated thymidine into total SV40 DNA in
HDACi treated or untreated infected cells. As shown in
Figure 3A, we observed a significant reduction in the
amount of tritiated thymidine incorporated into the SV40
DNA from treated cells compared to untreated controls.
For example, incorporation of tritiated thymidine was
reduced to 48 ± 7% following treatment with NaBu and to
22 ± 3% following treatment with TSA. The reduction in
the incorporation of the radiolabeled thymidine into
SV40 DNA following HDACi treatment indicated that
there was significantly less replication occurring following
treatment with the inhibitors.
Effects of HDACi treatment on SV40 Replication Figure 3
Effects of HDACi treatment on SV40 Replication. (a) BSC-1 cells infected for 48 hours with wild type 776 SV40 virus 
were either untreated or treated with 250 μM NaBu or 120 nM TSA and radiolabeled with methyl-[3H] thymidine. SV40 DNA 
was isolated and methyl-[3H] thymidine incorporation into newly replicating DNA was counted in a liquid scintillation analyzer 
and is represented as the percentage of methyl-[3H] thymidine incorporation relative to untreated cells. Data represented in 
the graph is Mean ± S.E. (n = 6). (b) 48 hour SV40 minichromosomes either untreated or treated with 250 μM NaBu or 120 
nM TSA were immune selected using 10 μl of antibody against RPA70. Data is expressed as percentage of SV40 minichromo-
somes containing RPA70 and represent the average of three independent experiments.Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
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In order to confirm that replication was affected by
HDACi treatment, we determined whether the percentage
of SV40 minichromosomes carrying RPA70, a protein
absolutely required for replication [17], was reduced fol-
lowing HDACi treatment. SV40 minichromosomes were
harvested from HDACi treated or untreated infected cells
48 hours post-infection and subjected to a ChIP analysis
using antibodies to RPA70 followed by real time PCR
quantitation. As shown in Figure 3B, approximately 0.047
± 0.008% of the minichromosomes isolated from
untreated SV40 infected cells at 48 hours post-infection
contained bound RPA70 and were presumably undergo-
ing replication. Following treatment with NaBu and TSA
the percentage of minichromosomes which contained
RPA70 decreased to 0.003 ± 0.001% and 0.004 ± 0.001%
respectively.
The inhibition in the uptake of tritiated thymidine and
reduction in the percentage of SV40 minichromosomes
containing bound RPA70 indicated that HDAC activity
played a role in determining the biological fate of the
SV40 minichromosomes as suggested by the results with
transcribing SV40 minichromosomes described above.
2.4. Inhibition of histone deacetylation results in an 
increase in occupancy of RNAPII on SV40 
minichromosomes
While the increase in SV40 minichromosomes which
carry RNAPII described above could account for the
observed stimulation of early and late transcription, it is
also possible that the stimulation of transcription
occurred at least in part as a result of the presence of more
RNAPII transcription complexes on each of the transcrib-
ing SV40 minichromosomes. In order to test this hypoth-
esis, we determined the occupancy of RNAPII on SV40
minichromosomes isolated at 30 minutes, 8 hours, and
48 hours post-infection from HDACi treated SV40
infected cells using an ISF analysis and compared the
results to the occupancy in untreated SV40 minichromo-
somes [15]. In an ISF analysis SV40 minichromosomes
containing a protein of interest such as RNAPII are bound
to agarose in a typical ChIP procedure by an antibody
which recognizes the protein. The minichromosomes
which are bound to agarose are then fragmented by soni-
cation. The DNA present in fragments which remain
bound to the agarose and the DNA in fragments which are
solubilized by the sonication are then amplified by PCR
with primers that recognize sites of interest in the SV40
genome. The occupancy of a protein in a site of interest is
defined as the percentage of the total DNA amplified from
the site which remained bound to the agarose after the
sonication.
The results of this analysis are shown in Table 1. In our
initial experiments we compared treated and untreated
minichromosomes isolated in parallel in three separate
preparations. The untreated controls showed the same
amount of RNAPII occupancy as our previous published
results [15]. In order to obtain similar statistical signifi-
cance for the treated samples we prepared additional sam-
ples in parallel which had been treated with either NaBu
or TSA (n = 5).
At 30 minutes post-infection HDACi treatment had rela-
tively little effect on RNAPII occupancy in SV40 minichro-
mosomes compared to untreated controls. Occupancy in
the early region was 72 ± 2.0% (NaBu) and 78 ± 1.5%
(TSA) compared to 63 ± 1.5%. Occupancy in the late
region was 40 ± 1.0% (NaBu) and 39 ± 1.5% (TSA) com-
pared to 34 ± 2.0%. Occupancy in the promoter was 53 ±
2.0% (NaBu) and 57 ± 1.0% (TSA) compared to 51 ±
1.5%.
However, at 8 hours post-infection occupancy by RNAPII
of the early region and promoter but not the late region
were significantly increased following HDACi treatment.
Occupancy in the early region was 67 ± 1.0% (NaBu) and
65 ± 2.0% (TSA) compared to 43 ± 1.5%. Occupancy in
the promoter was 51 ± 1.0% (NaBu) and 59 ± 2.5% (TSA)
compared to 28 ± 3.5%. Occupancy in the late region was
58 ± 2.0% (NaBu) and 64 ± 1.0% (TSA) compared to 51
± 3.0%.
At 48 hours post-infection HDACi treatment resulted in a
substantial increase in RNAPII occupancy in the late
region with less effect on the early region and no effect on
Table 1: Relative occupancy of RNA Polymerase II on the SV40 
genome after treatment with HDACi.
30 Min 8 Hour 48 Hour
EARLY Untreated 63 ± 1.5 43 ± 1.5 42 ± 2.0
NaBu Treated 72 ± 2.0 67 ± 1.0* 54 ± 2.5
TSA Treated 78 ± 1.5 65 ± 2.0* 57 ± 1.0
LATE Untreated 34 ± 2.0 51 ± 3.0 52 ± 2.5
NaBu Treated 40 ± 1.0 58 ± 2.0 84 ± 1.0**
TSA Treated 39 ± 1.5 64 ± 1.0 89 ± 2.5**
PROMOTER Untreated 51 ± 1.5 28 ± 3.5 60 ± 0.5
NaBu Treated 53 ± 2.0 51 ± 1.0* 62 ± 3.0
TSA Treated 57 ± 1.0 59 ± 2.5* 67 ± 1.5
**P < 0.001; * P < 0.05 (Student's t test). Untreated SV40 
minichromosomes or SV40 minichromosomes treated with 250 μM 
NaBu or 120 nM TSA were isolated from cells infected with 776 wild-
type virus for 48 hours. Purified SV40 minichromosomes were 
immunoprecipitated with 10 μl antibody to RNA polymerase II using 
the ISF technique and PCR amplified using primer sets to the early, 
late and promoter regions. Data in the table is represented as Mean ± 
S.E (n = 5 for treated samples and n = 3 for untreated control 
samples).Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
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the promoter. Occupancy in the late region was 84 ± 1.0%
(NaBu) and 89 ± 2.5% (TSA) compared to 52 ± 2.5%.
Occupancy in the early region was 54 ± 2.5% (NaBu) and
57 ± 1.0% (TSA) compared to 42 ± 2.0%, while occupancy
in the promoter was 62 ± 3.0% (NaBu) and 67 ± 1.5%
(TSA) compared to 60 ± 0.5%.
The large increase in RNAPII occupancy on the late region
at 48 hours post-infection in conjunction with the contin-
ued high occupancies in the other regions of the genome
indicated that there was an overall increase in the number
of RNAPII transcription complexes which could contrib-
ute to the increase in late mRNA observed at this time. The
large increase in RNAPII occupancy in the promoter at 8
hours post-infection suggested that histone deacetylation
played a role in the down-regulation of early transcription
which normally occurred at this time.
2.5. HDAC inhibition does not affect binding of p300 to 
RNAPII in transcribing minichromosomes
Since p300 was associated with RNAPII and hyper-
acetylated H4 and H3 in the coding regions of SV40 min-
ichromosomes during transcription [12] and was
absolutely necessary for SV40 transcription [12], we won-
dered whether HDACi treatment which typically results in
increased histone hyperacetylation would allow the
RNAPII transcription complexes in a coding region to
function without associated p300. In order to address this
question, SV40 minichromosomes were isolated from
HDACi treated or untreated infected cells and the mini-
chromosomes subjected to an Immune Selection Frag-
mentation followed by immunoprecipitation (ISFIP)/Re
Chromatin Immunoprecipitation (ReChIP) analysis
[12,15]. In an ISFIP/ReChIP analysis SV40 minichromo-
somes containing a protein of interest are immune
selected with antibody to the protein and the minichro-
mosomes fragmented by sonication as in an ISF analysis.
The chromatin fragments which were originally bound to
agarose are then eluted, and the eluted fragments and the
solubilized fragments are each subjected to a second ChIP
analysis with antibody to a second protein of interest. If
the two proteins of interest are associated in the minichro-
mosomes at some site in the genome, we would expect to
find a PCR amplification product from the ReChIP por-
tion of the analysis. In contrast if the two proteins are not
associated we would expect to find an amplification prod-
uct from the ISFIP portion of the analysis.
A typical example of this type of analysis is shown in Fig-
ure 4. Consistent with our previous publication using
untreated minichromosomes [12], we observed p300 spe-
cifically associated with the RNAPII in the ReChIP fraction
(lane 6) and not in the ISFIP fraction (lane 3). Hyper-
acetylated H4 which was used as a positive control was
found in both the ReChIP and ISFIP fractions (lanes 5 and
2 respectively) as we have previously reported [12]. When
minichromosomes from cells treated with NaBu or TSA
were analyzed, similar results were obtained. p300 was
again found associated with the ReChIP fraction (lane 6)
and not the ISFIP fraction (lane 3), while hyperacetylated
H4 was found associated with both fractions (lanes 5 and
2). These results indicated that p300 was still associated
with RNAPII despite the fact that the histones present in
the coding region had been extensively hyperacetylated by
the HDACi treatment.
3. Discussion
Our current studies have shown that HDACi treatment
can potentially stimulate SV40 transcription at the appro-
priate times during infection by increasing the number of
minichromosomes carrying RNAPII through increased
recruitment and by increasing the number of RNAPII mol-
ecules on the transcribed region of a minichromosome
presumably through increased re-initiation. Interestingly,
stimulation did not occur at all (the late genes at early
times) or occurred only minimally (the early genes at late
times) during the infection when the genes were naturally
repressed, indicating that inhibition of HDAC activity was
not sufficient by itself to overcome the normal repression
of the genes at these times. The differential effects of
HDACi treatment on the early and late genes at different
time in infection were consistent with the observation
Association of p300 with transcribing SV40 minichromo- somes after HDACi treatment Figure 4
Association of p300 with transcribing SV40 minichro-
mosomes after HDACi treatment. Unfixed SV40 mini-
chromosomes treated with 250 μM NaBu or 120 nM TSA 
were isolated from cells infected with 776 wild-type virus for 
48 hours, immunoprecipitated with RNAPII, and then sub-
jected to an ISFIP/ReChIP analysis with antibody against p300. 
The samples were amplified by simplex PCR with primer sets 
to the late region. The position of the amplification product 
from the wild-type 776 DNA is indicated. Lane 1, ISFIP input 
fraction; lane 2, ChIP with 7.5 μl of hyperacetylated histone 
H4 antibody (ISFIP); lane 3, ChIP with 10 μl of p300 antibody 
(ISFIP); lane 4, ReChIP input fraction; lane 5, ChIP with 7.5 μl 
of hyperacetylated histone H4 antibody.Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
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that at any given time only between 2 and 20% of eukary-
otic genes undergo significant stimulation of transcription
following HDACi treatment [18].
HDACi treatment had no apparent effect on the associa-
tion between p300 and RNAPII, which we have previously
demonstrated to be necessary for transcription and his-
tone hyperacetylation in the coding region of genes [12]
suggesting that the targeting of HATs and HDACs to the
RNAPII transcription complex occur independently.
The increased occupancy of the SV40 promoter and early
coding region at 8 hours post-infection along with a two
fold increase in early transcription after HDACi treatment
suggested that HDACs may play a role in the down-regu-
lation of SV40 early transcription which normally
occurred at that time. Similar increases in occupancy were
previously observed in the SV40 deletion mutant cs1085
which does not undergo down-regulation due to the ina-
bility of T-antigen to bind to its regulatory site in the pro-
moter [15]. This suggested role for HDACs in SV40
regulation is consistent with the recent observation that T-
antigen represses CBP-mediated transcription through
interactions with HDAC1 [19].
Although there have been no previous studies of the
effects of HDACi treatment on SV40 early and late expres-
sion during a lytic infection, the effects of NaBu on T-anti-
gen expression in a non-permissive host [20] and SV40
transformed cells [21] have been investigated. In the
former case NaBu appeared to cause a maximum stimula-
tion of early transcription at later times in infection. In
SV40 transformed cells NaBu appeared to cause approxi-
mately a five fold increase in T-antigen protein and
mRNA, an increase similar to what was observed in our
experiments.
Since HDACs are thought to be recruited to the promoters
of many genes during repression of transcription [22], one
way that HDAC inhibitors are thought to function is by
blocking the recruitment of HDACs to promoters and
thereby their repressive functions [23]. Our observation
that HDAC inhibitors are capable of increasing the size of
the pool of transcribing SV40 minichromosomes at early
and late times is consistent with this suggested model. The
fact that the HDAC inhibitors also cause a reduction in the
size of the pool of replicating SV40 minichromosomes at
late times suggests that HDAC activity may play a role in
determining the biological fate of newly replicated SV40
minichromosomes. This suggestion that the fate of newly
replicated SV40 minichromosomes may be determined in
part by HDAC function is consistent with previous work
which showed that treatment of SV40 infected cells late in
infection with NaBu reduced the fraction of newly repli-
cated minichromosomes which became committed to the
encapsidation pathway [24].
Characteristically, many genes which are responsive to
HDAC inhibitors contain specific response elements such
as Sp1/Sp3 binding sites [22]. In this regard it is interest-
ing to note that the SV40 regulatory region contains a
series of Sp1 binding sites known as the 21 bp repeats
which are required for transcription [25]. Moreover, we
have shown previously that these Sp1 binding sites play a
role in the nucleosomes phasing associated with the gen-
eration of a nucleosomes-free SV40 promoter region dur-
ing initiation of transcription [26]. However, because of
the complexity of the SV40 regulatory region and the pres-
ence of multiple transcription factor binding sites, we can-
not exclude the possibility that interactions through other
regulatory sequences may also be affected by HDACi treat-
ment.
While the stimulation of transcription and increased
occupancy of the late coding region at 48 hours post-
infection following treatment correlates very well with a
marked increase in hyperacetylated histones which we
previously observed following NaBu treatment [12], it is
also possible that the effects of treatment at 48 hours post-
infection or other times is a result of an indirect effect of
the HDAC inhibitors. As a consequence of their ability
under certain conditions to deregulate specific genes
including transcription factors such as Sp1 [27] or critical
regulatory proteins such as waf1 [23], some of the effects
of the HDAC inhibitors may be mediated through one or
more of these aberrant regulatory factors acting on a gene
of interest.
4. Materials and methods
4.1. Cells and viruses
SV40 virus and chromatin were prepared in the BSC-1 cell
line of monkey kidney cells (ATCC). The 776 SV40 wild
type virus was a gift from Dr Daniel Nathans.
4.2. Cell culture and infections
BSC-1 cells were maintained and infected at 10 pfu as pre-
viously described [12]. Treated cells were grown in the
presence of 250 μM NaBu or 120 nM trichostatin A
[Sigma] for 24 hour (in case of 8 hours and 48 hours post
infection) or for 12 hours (in case of 30 mins post infec-
tion) prior to harvesting the minichromosomes.
4.3. Preparation of SV40 minichromosomes
SV40 minichromosomes from treated or untreated
infected cells were harvested at 30 minutes, 8 hours or 48
hours post-infection and purified by glycerol gradient cen-
trifugation as previously described [26,28]. Gradient frac-
tions three, four and five, which contained SV40Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
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minichromosomes, were combined for subsequent analy-
sis.
4.4. Measurement of incorporation of Tritiated Thymidine 
into DNA
At 24 hours post-infection, SV40 infected BSC-1 cells were
either treated with 250 μM of sodium butyrate (NaBu) or
120 nM of trichostatin A (TSA) or left untreated. Follow-
ing a twenty four hour incubation, the HDACi treated or
untreated cells were allowed to replicated in the presence
of 500 μl of [methyl-3H-thymidine] (5 mCi, Amersham)
for one hour. The cells were then washed twice in chilled
PBS and extracted using the Hirt method of viral DNA
extraction [29]. Purified SV40 DNA was dissolved in 20 μl
of TE buffer. Five μl of the solution was placed in a scintil-
lation vial with 3 ml of Ecoscint A scintillation solution
(National Diagnostics) and counted in a liquid scintilla-
tion analyzer (Beckmann LS6500). The counts per minute
(cpm) reflected the amount of radiolabel that was incor-
porated into the DNA.
4.5. Chromatin Immunoprecipitation and Immune 
Selection Fragmentation (ISF)
Untreated, NaBu treated and TSA treated SV40 minichro-
mosomes were immunoprecipitated with 10 μl antibody
to RNA Polymerase II (sc-900; Santa Cruz Biotechnology);
10 μl antibody to RPA 70 (sc-25376; Santa Cruz Biotech-
nology) or 7.5 μl antibody to hyperacetylated H4
(06–866 Upstate) using the reagents and protocol sup-
plied by Upstate for the analysis of hyperacetylated H4
with minor modifications as previously described. In the
final step of chromatin immunoprecipitation the pelleted
agarose was resuspended in 200 μl of TE buffer. The resus-
pended agarose was sonicated and prepared for subse-
quent analysis as previously described [15,12,30].
4.6. Immune Selection Fragmentation followed by a 
second Immunoprecipitation (ISFIP)
Untreated, NaBu treated or TSA treated SV40 minichro-
mosomes were immunoprecipitated with antibody to
RNAP II as described above for the ISF procedure. In the
final step of ISF, the soluble fraction obtained after soni-
cation was used as the secondary input sample (200 μl)
and immunoprecipitated with antibody to p300, (sc-584,
Santa Cruz Biotechnology). The immunoprecipitation
was carried out as described previously [12,30].
4.7. Re Chromatin Immunoprecipitation (Re-ChIP)
ReChIP was performed according to the procedure
described by IJpenberg et al (2004) with minor modifica-
tions [31]. Untreated, NaBu treated or TSA treated SV40
minichromosomes were immunoprecipitated with anti-
body to RNAPII as described above for the ISF procedure.
In the final step of ISF, the bound fraction was eluted
twice with 200 μl Immunopure Gentle Ag/Ab Elution
Buffer (Pierce). The bound fraction was incubated for 15-
minute with elution buffer at room temperature and the
eluted chromatin recovered by centrifugation. The eluates
were pooled as the secondary input sample (200 μl) and
immunoprecipitated with antibody to p300 (sc-584,
Santa Cruz Biotechnology). The immunoprecipitation
was carried out as described previously [15,12,30].
4.8. Preparation of DNA for PCR
Samples were prepared for PCR by phenol/chloroform
extraction followed by ethanol precipitation in the pres-
ence of paint pellet co-precipitant (Novagen) as previ-
ously described [15,12,30]. Approximately 100 μl of
protein A agarose eluates was purified using phenol/chlo-
roform. The aqueous phase (125 μl) was added to a PCR
tube that contained 3 μl of pellet paint co-precipitant and
12.5 μl of 3 M sodium acetate, pH 5.2 (Novagen). The
samples were mixed and 280 μl of 100% ethanol added to
each. Following 10-min incubation at room temperature,
the samples were centrifuged at 8000 × g for 5 min and the
supernatant discarded. The samples were washed with
70% ethanol, vortexed, incubated for 5 min, and then
centrifuged at 8000 × g for 5 min. The supernatant was
again discarded and the samples were dried in a vacuum.
4.9. PCR amplifications
DNA was amplified from three different regions of the
SV40 genome (the early coding region, the late coding
region and the promoter) in a Perkin-Elmer Model 480
thermal cycler using Ampli Taq Gold DNA Polymerase
(Applied Biosystems) with primer sets
5'GCTCCCATTCATCAGTTCCA3' and 5'
CTGACTTTGGAGGCTTCTGG3' for the amplification of
the early region (nt 4540–4949), 5'
CAGTGCAAGTGCCAAAGATC3' and
5'GCAGTTACCCCAATAACCTC3' for amplification of the
late region (nt 1566–1878) and
5'GCAAAGCTTTTTGCAAAAGCCTAGGCCT3'and
5'CGAACCTTAACGGAGGCCTGGCG3' for amplification
of the promoter region (nt 5168-420). A master mix con-
taining all the required constituents was prepared accord-
ing to the instructions supplied with the DNA polymerase
in advance and kept at -20°C until required. Immediately
before use, the master mix was thawed and a volume cor-
responding to 30 μl for each sample to be amplified was
removed to prepare a working mix. The working mix was
then prepared by adding the DNA polymerase to the mas-
ter mix in the ratio of 0.5 μl per 30 μl of master mix. Fol-
lowing thorough mixing, the 30 μl of working mix was
added to each previously prepared PCR tube containing a
sample of template DNA to be amplified. The tubes were
gently vortexed to suspend the pelleted DNA present in
the tubes. When suspension was complete, the samples
were overlaid with two drops of molecular biology grade
mineral oil (Sigma). All previous manipulations were per-Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
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formed in a Nuaire biological safety cabinet Model
NU_425-400. The samples were centrifuged for 1 min at
10,000 × g in an Eppendorf micro centrifuge, and the PCR
amplifications were hot started by heating the tubes for 2
min and 30 sec at 95°C. The DNA was amplified for 45
cycles with each cycle consisting of annealing at 60°C for
early region, 64°C for late region and 70°C for the pro-
moter region for 1 min, DNA synthesis for 1 min at 72°C
and denaturation at 95°C for 1 min.
4.10. Real Time PCR
DNA was amplified from the late region of the SV40
genome in a Cepheid Smart Cycler 2.0 System using the
QuantiTect SYBR Green Real Time PCR Kit (QIAGEN,
Valencia, CA) using the same primer sets described above.
The DNA was amplified for 40 cycles with each cycle con-
sisting of denaturation at 95°C for 30 sec, annealing at
64°C 30 sec, DNA synthesis for 1 min at 72°C.
4.11. Real Time Reverse Transcription PCR
Real Time RT-PCR analysis was performed using the
QuantiTect SYBR Green RT-PCR kit (QIAGEN, Valencia,
CA). Primer sets for the early and late coding region were
same as described above. A master mix containing 25 μl of
2× QuantiTect SYBR Green RT-PCR Master Mix (1×),
primer sets (0.5 μM of each primer), 0.5 μl of QuantiTect
RT Mix (0.5 μl/reaction), template RNA (500 ng/reaction)
and RNase free water to make the final volume of the mix
to 50 μl. The reverse transcription step to synthesize the
first strand cDNA was done at 50°C for 30 min, followed
by a 15 min initial PCR activation step at 95°C to activate
the HotStarTaq DNA Polymerase. The DNA was amplified
for 40 cycles with each cycle consisting of denaturation at
94°C for 1 min, annealing at 60°C for early region
GAPDH, 64°C for late region for 1 min, DNA synthesis
for 1 min at 72°C and a final extension at 72°C for 10
min
4.12. Analysis of PCR amplification products
Following PCR amplification of the DNA samples, the
products were separated on 2.4% submerged agarose gels
(Sigma) by electrophoresis. The separated products were
visualized by staining with ethidium bromide and elec-
tronically photographed using UVP GDS8000 Gel Docu-
mentation System (Ultra Violet Products).
4.13. Scanning densitometry
Quantitation of agarose gels was done with Molecular
Analyst (Version 1.4) from Bio-Rad. Using Molecular ana-
lyst images were obtained by importing those that were
captured with UVP GDS8000 Gel Documentation System.
On importing the image, quantitation was performed
with the Volume Analysis function to determine the per-
cent volume of DNA bands of interest. The Local Back-
ground subtraction function was utilized to normalize
background noise.
4.14. Data representation
Delta CT values were calculated as follows; ΔCT = CT
(input material) - CT (ChIP sample with antibody to
RNAP II [transcribing minichromosomes] or RPA 70 [rep-
licating Minichromosomes]). ΔCT was expressed either as
a percentage of minichromosomes containing the epitope
for a particular antibody. Statistical analysis was per-
formed using two tailed Student's t test.
4.15. Western blotting
Protein extracted from untreated, NaBu treated and TSA
treated 48 hour wild type 776 SV40 virus infected cells
were harvested and lysed using 1× RIPA buffer. Protein
levels were determined with the Micro BCA™ Protein
Assay kit (Pierce Biotechnology, Inc., Rockford, IL). The
proteins were separated on a 4–20% PAGEr® polyacryla-
mide gel (Cambrex BioScience Inc., Walkersville, MD)
under denaturing conditions and electroblotted onto
PVDF membrane (Millipore, Billerica, MA). Antibodies
used for western blotting were goat polyclonal anti
GAPDH (sc-20357); Santa Cruz Biotechnology; rabbit
GST-fusion anti VP1 [32] and anti T Antigen.
5. Abbreviations
RNAP II: RNA Polymerase II, NaBu: sodium butyrate; TSA:
trichostatin A; HDACi: HDAC inhibitors; ISF: immune
selection and fragmentation; ISFIP: ISF followed by a sec-
ond immunoprecipitation; ReChIP: re-chromatin immu-
noprecipitation; GAPDH: glyceraldehydes-3-phosphate
dehydrogenase; VP1: viral protein 1; P.I.: post-infection
6. Competing interests
The author(s) declare that they have no competing inter-
ests.
7. Authors' contributions
LB performed the experiments and wrote the manuscript.
BM edited the manuscript and provided input into the
experiments. Both authors read and approved the final
manuscript.
8. Acknowledgements
We would like to thank Dr. Steve Tronick from Santa Cruz Biotechnology 
for his generosity in sharing the RNAPII, p300 and RPA 70 antibodies. We 
would also like to thank Dr Dan Simmons and Dr Ariella Oppenheim for 
sharing the T antigen and VP1 antibodies respectively. This work was sup-
ported by a grant from the National Institutes of Health 1R15GM074811-
01A1 to BM. LB was supported by a Doctoral Dissertation Assistantship 
Award from ND EPSCoR.
References
1. Saunders N DA Popa C, Jones S, Dahler A.: Histone deacetylase
inhibitors as potential anti-skin cancer agents.  Cancer Res
1999, 59(2):399-404.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2008, 5:43 http://www.virologyj.com/content/5/1/43
Page 11 of 11
(page number not for citation purposes)
2. Cress WD, Seto E: Histone deacetylases, transcriptional con-
trol, and cancer.  J Cell Physiol 2000, 184(1):1-16.
3. Wade PA: Transcriptional control at regulatory checkpoints
by histone deacetylases: molecular connections between
cancer and chromatin.  Hum Mol Genet 2001, 10(7):693-698.
4. Workman JL, Kingston RE: Alteration of nucleosome structure
as a mechanism of transcriptional regulation.  Annu Rev Bio-
chem 1998, 67:545-579.
5. Cummings JH: Short chain fatty acids in the human colon.  Gut
1981, 22(9):763-779.
6. Whiteley LO, Higgins JM, Purdon MP, Ridder GM, Bertram TA: Eval-
uation in rats of the dose-response relationship among
colonic mucosal growth, colonic fermentation, and dietary
fiber.  Dig Dis Sci 1996, 41(7):1458-1467.
7. Gray SG QCN Furge K, Guo X, Teh BT.: Microarray profiling of
the effects of histone deacetylase inhibitors on gene expres-
sion in cancer cell lines.  Int J Oncol 2004, 24:773-795.
8. Mitsiades CS MNS McMullan CJ, Poulaki V, Shringarpure R, Hideshima
T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M,
Libermann TA, Richon VM, Marks PA, Anderson KC.: Transcrip-
tional signature of histone deacetylase inhibition in multiple
myeloma: biological and clinical implications.  PNAS 2004,
101:540-545.
9. Peart MJ SGK van Laar RK, Bowtell DD, Richon VM, Marks PA, Hol-
loway AJ, Johnstone RW.: Identification and functional signifi-
cance of genes regulated by structurally different histone
deacetylase inhibitors.  PNAS 2005, 102:3697-3702.
10. Dokmanovic M MPA: Prospects: histone deacetylase inhibitors.
J Cell Biochem 2005, 96:293-304.
11. Rasheed WK JRW Prince HM.: Histone deacetylase inhibitors in
cancer therapy.  Expert Opin Investig Drugs 2007, 16(5):659-678.
12. Balakrishnan L, Milavetz B: Histone hyperacetylation in the cod-
ing region of chromatin undergoing transcription in SV40
minichromosomes is a dynamic process regulated directly
by the presence of RNA polymerase II.  J Mol Biol 2007,
365(1):18-30.
13. Van Lint C ES Verdin E.: The expression of a small fraction of
cellular genes is changed in response to histone hyper-
acetylation.  Gene Expr 1996, 5(245-53):.
14. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA,
Breslow R, Pavletich NP: Structures of a histone deacetylase
homologue bound to the TSA and SAHA inhibitors.  Nature
1999, 401(6749):188-193.
15. Balakrishnan L, Milavetz B: Reorganization of RNA polymerase
II on the SV40 genome occurs coordinately with the early to
late transcriptional switch.  Virology 2006, 345(1):31-43.
16. Eadara JK, Lutter LC: RNA polymerase locations in the simian
virus 40 transcription complex.  J Biol Chem 1993,
268(29):22020-22027.
17. Kelly TJ, Brown GW: Regulation of chromosome replication.
Annu Rev Biochem 2000, 69:829-880.
18. Adcock IM: HDAC inhibitors as anti-inflammatory agents.  Br
J Pharmacol 2007, 150(7):829-831.
19. Valls E, Blanco-Garcia N, Aquizu N, Piedra D, Estaras C, de la Cruz
X, Martinez-Balbas MA: Involvement of chromatin and histone
deacetylation in SV40 T antigen transcription regulation.
Nucleic Acids Res 2007, 35(6):1958-1968.
20. Mitsudomi T, Kimura G: Effects of sodium n-butyrate on entry
into S phase in resting rat 3Y1 cells infected with simian virus
40.  J Virol 1985, 56(3):951-957.
21. Goldberg YP, Leaner VD, Parker MI: Elevation of large-T antigen
production by sodium butyrate treatment of SV40-trans-
formed WI-38 fibroblasts.  J Cell Biochem 1992, 49(1):74-81.
22. Davie JR: Inhibition of histone deacetylase activity by
butyrate.  J Nutr 2003, 133(7 Suppl):2485S-2493S.
23. Monneret C: Histone deacetylase inhibitors for epigenetic
therapy of cancer.  Anticancer Drugs 2007, 18(4):363-370.
24. Roman A: Alteration in the simian virus 40 maturation path-
way after butyrate-induced hyperacetylation of histones.  J
Virol 1982, 44(3):958-962.
25. Dynan WS, Tjian R: Isolation of transcription factors that dis-
criminate between different promoters recognized by RNA
polymerase II.  Cell 1983, 32(3):669-680.
26. Hermansen R, Sierra MA, Johnson J, Friez M, Milavetz B: Identifica-
tion of Simian virus 40 promoter DNA sequences capable of
conferring restriction endonuclease hypersensitivity.  J Virol
1996, 70(6):3416-3422.
27. Ghosh AK, Mori Y, Dowling E, Varga J: Trichostatin A blocks
TGF-beta-induced collagen gene expression in skin fibrob-
lasts: involvement of Sp1.  Biochem Biophys Res Commun 2007,
354(2):420-426.
28. Friez M, Hermansen R, Milavetz B: Chromatin structure of the
simian virus 40 late promoter: a deletional analysis.  J Virol
1999, 73(3):1990-1997.
29. Hirt B: Selective extraction of polyoma DNA from infected
mouse cell cultures.  J Mol Biol 1967, 26(2):365-369.
30. Balakrishnan L, Milavetz B: Histone Hyperacetylation during
SV40 Transcription is Regulated By p300 and RNA Polymer-
ase II Translocation.  J Mol Biol 2007, 371(4):1022-1037.
31. IJpenberg A, Tan NS, Gelman L, Kersten S, Seydoux J, Xu J, Metzger
D, Canaple L, Chambon P, Wahli W, Desvergne B: In vivo activa-
tion of PPAR target genes by RXR homodimers.  Embo J 2004,
23(10):2083-2091.
32. Sandalon Z OA: Self-assembly and protein-protein interac-
tions between the SV40 capsid proteins produced in insect
cells.  Virology 1997, 237(2):414-421.